Fig. 1. Expression patterns of pyruvate kinases. (A) Number of cases of human normal prostate tissue samples and prostate adenocarcinoma tissue samples (belonging to three different tumor stages). (B) Normal prostate tissue and prostate adenocarcinoma tissue samples were immunostained for PKM2 by using the specific antibody. (C) PKM2 immunoreactive scoring between the normal prostate tissue samples and prostate adenocarcinoma tissue samples belonging to the three different tumor stages. (D) Comparison of PKM1 and PKM2 expression levels in seven cancer cell lines using GAPDH as an internal loading control. (CaCo: human epithelial colorectal adenocarcinoma cells; MCF-7: human breast adenocarcinoma cells; Ishikawa: human Asian endometrial adenocarcinoma cells; HCT 116: human colon carcinoma cells; Caki-1: human clear cell renal cell carcinoma; DU145: human prostate cancer cells; 786-O: human renal carcinoma cells from the kidney).